Parkinson’s disease is a progressive neurodegenerative disorder known to impact nearly 7.5 million people globally. Credit: Colin Behrens from Pixabay.

Atara Biotherapeutics has announced initial safety results from the Phase I clinical trial of its allogeneic T-cell immunotherapy ATA188 in patients suffering from progressive multiple sclerosis (MS).

ATA188 is designed to target specific Epstein-Barr virus (EBV) antigens believed to be involved in the pathogenesis of the chronic neurological autoimmune disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The primary objective of ATA188’s ongoing multi-centre, open-label, single-arm, dose-escalating Phase I trial is to assess safety and tolerability for progressive MS patients.

According to data, the first three dose cohorts of the T-cell immunotherapy product were found to be well-tolerated without dose-limiting toxicities or ≥3 grade treatment-related, treatment-emergent adverse events.

Atara Biotherapeutics senior vice-president and chief medical officer AJ Joshi said: “We are encouraged by the initial ATA188 safety and tolerability results from the first three cohorts.

“We continue to enrol patients with progressive MS in the fourth and final planned dose escalation cohort and look forward to presenting preliminary efficacy results from the initial cohorts of this study at a scientific congress in the second half of 2019.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase I trial is currently working towards the determination of a recommended Phase II dose (RP2D).

Atara intends to perform a randomised, double-blind, placebo-controlled Phase Ib extension period for this trial using the RP2D after the open-label, dose-escalation period is complete.

The trial’s key secondary endpoints include clinical improvement measures such as expanded disability status scale (EDSS) and MRI imaging, along with additional clinical activity measures.

A total of 24-30 primary and secondary progressive MS (PPMS, SPMS) patients are expected to be recruited across the US and Australia.